Search Media Items

Información básica de las desigualdades por cáncer en EE. UU., factores que contribuyen a la carga desproporcionada del cáncer en algunos grupos y ejemplos de desigualdades en incidencia y mortalidad entre ciertos grupos de la población.

This Childhood Cancer Genomics summary provides a brief synopsis of current knowledge about the genomic landscape of specific childhood cancers. Get detailed information about various genetic alterations and precision medicine concepts in childhood cancers in this summary for clinicians.

Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.

The RAS Initiative facilitates connections between and among researchers, bringing new ideas and technologies to bear on RAS. A guiding principle for these collaborations is close coordination with the activities at the Frederick National Laboratory for Cancer Research (FNLCR) Hub, so that new efforts can have a maximum amount of leverage on each other.

Aun cuando sea digno de celebración el que su niño haya terminado su tratamiento de cáncer, eso puede también traer nuevos retos. Usted puede preocuparse de que regrese el cáncer. Su niño puede batallar para acostumbrarse a nuevas rutinas.

¿Qué es delirio? Delirio es un estado mental confuse. Se explican las causas de delirio, formas de tratarlo y preguntas para hacer al doctor.

A feature-length Research Update article about exploring ways to use vesicles known as exosomes to develop new clinical tests and tools for patients with cancer.

Childhood vascular tumor treatment depends on the specific type and location, can involve surgery, and may be followed by chemotherapy or radiation. Targeted therapy, immunotherapy, and other medications may be used. Learn more about vascular tumors in this expert-reviewed summary.

Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection.

In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.